These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 13573368)

  • 1. Inhibition of ascites cell growth by combinations of 6-thioguanine and azaserine.
    SARTORELLI AC; LEPAGE GA
    Cancer Res; 1958 Sep; 18(8 Part 1):938-42. PubMed ID: 13573368
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of ascites tumor growth by 4-aminopyrazolo-(3,4-d)pyrimidine in combination with azaserine, 6-mercaptopurine, and thioguanine.
    HENDERSON JF; JUNGA IG
    Cancer Res; 1960 Dec; 20():1618-24. PubMed ID: 13713260
    [No Abstract]   [Full Text] [Related]  

  • 3. Metabolic effects of 6-thioguanine. I. Studies on thioguanine-resistant and-sensitive Ehrlich ascites cells.
    SARTORELLI AC; LEPAGE GA; MOORE EC
    Cancer Res; 1958 Nov; 18(10):1232-9. PubMed ID: 13596970
    [No Abstract]   [Full Text] [Related]  

  • 4. [On the effect of azaserine and azaserine with 6-mercaptopurine on the Yoshida sarcoma].
    YAMAGUCHI H; KURAHORI T; KUSUMOTO G; TERASHITA N; TABUCHI Y; ICHIHARA G; TOKITA Y; IKEDA E; FUKUI S
    Gan; 1956 Dec; 47(3-4):385-6. PubMed ID: 13415049
    [No Abstract]   [Full Text] [Related]  

  • 5. The development and biochemical characterization of resistance to azaserine in a TA 3 ascites carcinoma.
    SARTORELLI AC; LePAGE GA
    Cancer Res; 1958 May; 18(4):457-63. PubMed ID: 13536997
    [No Abstract]   [Full Text] [Related]  

  • 6. HOST-TUMOR-DRUG RELATIONSHIPS IN EXPERIMENTAL CHEMOTHERAPY SYSTEMS WITH ALLOGENEIC AND XENOGENEIC HOST-TUMOR COMBINATIONS.
    TELLER MN; WOLFF R; WAGSHUL SF
    Cancer Res; 1964 Jan; 24():114-9. PubMed ID: 14106153
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of ascites tumors with 4-aminopyrazolo (3,4-d)pyrimidine alone and in combination with azaserine, thioguanine, and 6-mercaptopurine.
    HENDERSON JF; JUNGA IG
    Cancer Res; 1961 Apr; 21(3)Pt 2():7-13. PubMed ID: 13713262
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies of a plasma-cell neoplasm of the mouse. I. Characterization of neoplasm 70429, including its sensitivity to various antimetabolites with the rapid development of resistance to azaserine, DON, and N-methylformamide.
    POTTER M; LAW LW
    J Natl Cancer Inst; 1957 Mar; 18(3):413-41. PubMed ID: 13406561
    [No Abstract]   [Full Text] [Related]  

  • 9. IV. Effect of O-diazoacetyl-L-serine (azaserine) on growth of various mouse and rat tumors.
    SUGIURA K; STOCK CC
    Proc Soc Exp Biol Med; 1955 Jan; 88(1):127-9. PubMed ID: 14357363
    [No Abstract]   [Full Text] [Related]  

  • 10. The metabolism of 6-thioguanine in normal and neoplastic tissues.
    MOORE EC; LePAGE GA
    Cancer Res; 1958 Oct; 18(9):1075-83. PubMed ID: 13596951
    [No Abstract]   [Full Text] [Related]  

  • 11. Azaserine resistance in a plasma-cell neoplasm without change in active transport of the inhibitor.
    ANDERSON EP; JACQUEZ JA
    Cancer Res; 1962 Jan; 22():27-37. PubMed ID: 13861221
    [No Abstract]   [Full Text] [Related]  

  • 12. The formation of 6-mer captopurine riboside phosphate in ascites tumor cells.
    PATERSON AR
    Can J Biochem Physiol; 1959 Aug; 37(8):1011-23. PubMed ID: 13671389
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of combinations of azaserine and of 6-diazo-5-oxo-L-norleucine with purine analogs and other antimetabolites on the growth of two mouse mammary carcinomas.
    TARNOWSKI GS; STOCK CC
    Cancer Res; 1957 Nov; 17(10):1033-9. PubMed ID: 13489704
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytochemical effects of azaserine on Ehrlich ascites tumor cells; action on deoxyribose nucleic acid (DNA) and total protein.
    LINDNER A
    AMA Arch Pathol; 1957 Jun; 63(6):532-9. PubMed ID: 13423969
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolic effects of 6-thioguanine. II. Biosynthesis of nucleic acid purines in vivo and in vitro.
    SARTORELLI AC; LEPAGE GA
    Cancer Res; 1958 Dec; 18(11):1329-35. PubMed ID: 13608442
    [No Abstract]   [Full Text] [Related]  

  • 16. Synthesis and cytotoxic activity of imidazo[1,2-a]-1,3,5-triazine analogues of 6-mercaptopurine.
    Saczewski F; Maruszak M; Bednarski PJ
    Arch Pharm (Weinheim); 2008 Feb; 341(2):121-5. PubMed ID: 18186543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of resistance to 6-mercaptopurine in a subline of the Ehrlich ascites carcinoma.
    PATERSON AR
    Can J Biochem Physiol; 1960 Oct; 38():1117-27. PubMed ID: 13733289
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of root growth by azaserine.
    NORMAN AG
    Science; 1955 Feb; 121(3137):213-4. PubMed ID: 13237973
    [No Abstract]   [Full Text] [Related]  

  • 19. Chromatographic studies of purine metabolism. IV. Reversal of azaserine-induced inhibition by phenylalanine and tryptophan.
    TOMISEK AJ; REID MR; SKIPPER HE
    Cancer Res; 1959 Jun; 19(5):489-93. PubMed ID: 13663035
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
    Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
    Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.